Morga A, Zimmermann L, Valluri U, Siddiqui E, McLeod L, Bender RH. Validation and application of thresholds to define meaningful change in vasomotor symptoms frequency: analysis of pooled SKYLIGHT 1 and 2 data. Adv Ther. 2024 May 22. doi: 10.1007/s12325-024-02849-2
Bektas M, Bell T, Khan S, Tumminello B, Fernandez MM, Heyes C, Oton AB. Desmoid tumors: a comprehensive review. Adv Ther. 2023 Sep;40(9):3697-722. doi: 10.1007/s12325-023-02592-0.
Ervin C, Norcross L, Mallya UG, Fehnel S, Mittleman RS, Webster M, Haqq AM, Haws RM. Interview-based patient- and caregiver-reported experiences of hunger and improved quality of life with setmelanotide treatment in bardet-biedl syndrome. Adv Ther. 2023 May;40(5):2394-411. doi: 10.1007/s12325-023-02443-y
Kim N, Brown TM, Burudpakdee C, Kanu C, Woodard K, Fehnel S, Morrison C, Nadglowski J, Nadolsky K, Kolotkin RL. Development of an assessment tool for completion by patients with overweight or obesity. Adv Ther. 2023 Jan;40(1):174-93. doi: 10.1007/s12325-022-02334-8
Herring WL, Gould IG, Wittrup-Jensen V, Ertle J, Kuti E, Wolowacz S. Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes. J Comp Eff Res. 2022 Dec 1;11(18):1349-63. doi: 10.2217/cer-2021-0194
Martin S, Chen K, Harris N, Vera-Llonch M, Krasner A. Development of a patient-reported outcome measure for chronic hypoparathyroidism. Adv Ther. 2019 Aug;36(8):1999-2009. doi: 10.1007/s12325-019-00999-2
Purser MF, Mladsi DM, Beckman A, Barion F, Forsey J. Expected budget impact and health outcomes of expanded use of vagus nerve stimulation therapy for drug-resistant epilepsy. Adv Ther. 2018 Oct;35(10):1686-96. doi: 10.1007/s12325-018-0775-0.
Joshi K, Muser E, Xu Y, Schwab P, Datar M, Suehs B. Adherence and economic impact of paliperidone palmitate versus oral atypical antipsychotics in a Medicare population. J Comp Eff Res. 2018 Aug;7(8):723-35. doi: 10.2217/cer-2018-0003
Nguyen Thi Nhan P, Van Toan D, Que Huong T, Minh Nguyet D, Thanh Dao T, Minh Tri L, Khac Minh T, Hoc TP Y. 3D-pharmacophore modeling and its application on allosteric inhibitors of rac serin/threonin protein kinase AKT1. Journal of Ho Chi Minh City Pharmacy Association. 2018;22(S1):380-8.
Ervin CM, Reasner DS, Hanlon JT, Fehnel SE. Exploring the diabetic gastroparesis patient experience: patient exit interviews. Adv Ther. 2017 Dec;34(12):2680-92. doi: 10.1007/s12325-017-0632-6
Meyers J, Gajria K, Candrilli SD, Fridman M, Sikirica V. The impact of adjunctive guanfacine extended release on stimulant adherence in children/adolescents with attention-deficit/hyperactivity disorder. J Comp Eff Res. 2017 Mar;6(2):109-25. doi: 10.2217/cer-2016-0039
Stull DE, McBride D, Houghton K, Finlay AY, Gnanasakthy A, Balp MM. Assessing changes in chronic spontaneous/idiopathic urticaria: comparisons of patient-reported outcomes using latent growth modeling. Adv Ther. 2016 Feb;33(2):214-24. doi: 10.1007/s12325-016-0282-0
Hess LM, Rajan N, Winfree K, Davey P, Ball M, Knox H, Graham C. Cost analyses in the US and Japan: a cross-country comparative analysis applied to the PRONOUNCE trial in non-squamous non-small cell lung cancer. Adv Ther. 2015 Dec 9;32(12):1248-62. doi: 10.1007/s12325-015-0270-9
Kitchen H, Rofail D, Heron L, Sacco P. Cognitive impairment associated with schizophrenia: a review of the humanistic burden. Adv Ther. 2012 Feb;29(2):148-62.
Ribeiro-Oliveira Jr A, Mol SS, Twiss J, Alencar GA, Miranda PA, Naves LA, Azevedo MF, Basilio FM, Boguszewski CL, Nogueira KC, Vilar L, Koltowska-Haggstrom M, McKenna SP. The brazilian version of the Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA): four-stage translation and validation. Arq Bras Endocrinol Metabol. 2010 Dec;54(9):833-41.
Small M, Vickers AD, Anderson P, Kay S. The patient-physician partnership in asthma: real-world observations associated with clinical and patient-reported outcomes. Adv Ther. 2010 Sep;27(9):591-9. doi: 10.1007/s12325-010-0054-1